Shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) saw unusually-strong trading volume on Monday . Approximately 119,870 shares traded hands during trading, an increase of 11% from the previous session’s volume of 108,352 shares.The stock last traded at $8.57 and had previously closed at $8.35.

Several research analysts recently weighed in on AQXP shares. Needham & Company LLC started coverage on shares of Aquinox Pharmaceuticals in a research note on Thursday, May 12th. They set a “buy” rating and a $25.00 price objective on the stock. Canaccord Genuity set a $22.00 price objective on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, July 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Aquinox Pharmaceuticals presently has an average rating of “Buy” and an average price target of $19.86.

The company’s market cap is $148.88 million. The company has a 50 day moving average of $7.21 and a 200 day moving average of $8.54.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. Analysts anticipate that Aquinox Pharmaceuticals Inc. will post ($1.79) earnings per share for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.